retatrutide fda status 2025 is the most significant weight-loss pharmaceutical currently in clinical development., Phase 3 TRIUMPH-4 trial results (published December 2025) showed average body weight reduction of FDA Warns Companies Over Compounded

The deals with the drug makers are part of a wider initiative to bring drug prices paid by Americans closer to prices paid in other developed countries a concept sometimes called most favored nation pricing.

These data are line with pharmacodynamic results from other studies with SAR425899 14 , confirming the drug to be a potent GLP-1 receptor agonist

Update End of January, 2026: If you are a current WW member, you might notice that the WW app has updated to the new logo, but you arent seeing the new features yet

Valuations for the two pharmaceutical companies (Novo Nordisk and Eli Lilly) at the core of this trend have rapidly increased as a result